LILRB2 and metabolic dysfunction-associated steatohepatitis: As immunosuppression has been suggested to be effective for ameliorating hepatic inflammation and fibrosis in NASH3, we speculated that LILRB2/PirB, as immune-inhibitory receptors, would be potential targets for NASH therapy.